This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This BMPR2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 28-59 amino acids from the N-terminal region of human BMPR2.
KO Validated
BMPR2
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50
For FACS starting dilution is: 1:10~50
Restrictions
For Research Use only
Format
Liquid
Concentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
BMPR2
(Bone Morphogenetic Protein Receptor, Type II (serine/threonine Kinase) (BMPR2))
BMPR2 is a member of the bone morphogenetic protein (BMP) receptor family of transmembrane serine/threonine kinases. The ligands of this receptor are BMPs, which are members of the TGF-beta superfamily. BMPs are involved in endochondral bone formation and embryogenesis. These proteins transduce their signals through the formation of heteromeric complexes of 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding. Mutations in BMPR2 have been associated with primary pulmonary hypertension.